Compare Natera Inc. Common Stock (NTRA) vs SK Hynix (SKHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs SK Hynix — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while SK Hynix trades at $137.16 (market cap $768.83B). The key difference: SK Hynix is far larger — about 13.5× Natera Inc. Common Stock's market cap, and SK Hynix pays a 0.07% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and SK Hynix for 12 Days on average.
| NTRA | SKHY | |
|---|---|---|
Market Cap | $57.03B | $768.83B |
Volume | 1,131,157 | 21,786,972 |
Sector | Health | Technology |
52-Week High | $425.64 | $198.63 |
52-Week Low | $179.42 | $126.79 |
Typical Hold Time | 0 Days | 12 Days |
Enterprise Value | $56.18B | $718.72B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SKHY trades at $157.06, down 3.15% amid a sector-wide tech selloff driven by Fed rate hike concerns and competitive threats from Chinese chipmaker CXMT. The stock shows strong fundamentals with a P/E of 9.27, net income margin of 85.62%, and consistent earnings beats. Technical indicators are bearish with moving averages signaling selling pressure, though oscillators suggest potential oversold conditions. Recent news highlights AI memory demand growth but also increased competition risks.
Despite near-term volatility, SKHY maintains robust profitability and analyst consensus remains bullish with a $242 price target representing 54% upside. Key risks include Chinese competition and macroeconomic pressures, but the company's leadership in AI memory and strong financial metrics support long-term growth potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About SK Hynix
SK hynix is a South Korean semiconductor company that manufactures memory products, including DRAM and NAND flash. Its high-bandwidth memory (HBM) products are designed for high-performance computing and AI applications.
Read more on SKHY →
